证券代码：603222 证券简称：济民健康 公告编号：2025-051 济民健康管理股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | 累计已回购股数 | 200.55万股 | | 累计已回购股数占总股本比例 | 0.38% | | 累计已回购金额 | 1,208.9万元 | | 实际回购价格区间 | 5.87元/股~6.13元/股 | 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况 ...

Core Viewpoint - Jimin Health announced the release of 17.64 million shares pledged by Shuangge Group, which represents 14.37% of Shuangge's holdings and 3.36% of the company's total share capital [1] Group 1: Share Pledge Details - The release of the pledged shares occurred on October 30, 2025 [1] - After the release, Shuangge Group has a total of 76.50 million shares pledged, accounting for 62.32% of its holdings and 14.57% of the company's total share capital [1] - As of the announcement date, the controlling shareholder and its concerted parties hold a total of 228.56 million shares, with 14.09 million shares pledged, which is 61.65% of their holdings and 26.83% of the company's total share capital [1]

Core Viewpoint - The company announced a share repurchase plan with a budget of 100-200 million yuan, aimed at employee stock ownership plans or equity incentives, with a duration of 12 months from board approval [1] Group 1: Share Repurchase Details - The company plans to repurchase shares through centralized bidding starting from March 28, 2025 [1] - As of October 31, 2025, the company has repurchased a total of 2.0055 million shares, accounting for 0.38% of the total share capital [1] - The total amount spent on the repurchase is 12.089 million yuan, with a repurchase price range of 5.87-6.13 yuan per share [1] Group 2: Implementation Status - As of October 2025, the company has not implemented any further repurchase actions [1]

Core Viewpoint - Jimin Health (603222.SH) announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Summary by Categories Share Buyback Details - As of October 31, 2025, the company has repurchased a total of 2.0055 million shares, which represents 0.3819% of the total share capital [1] - The highest purchase price for the shares was 6.13 CNY per share, while the lowest was 5.87 CNY per share [1] - The total amount spent on the buyback, excluding transaction fees, was 12.089 million CNY [1]

Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]

Core Points - The company has announced a share repurchase plan, allowing for the buyback of shares at a price not exceeding RMB 10.00 per share, with a total repurchase amount between RMB 100 million and RMB 200 million, to be executed within 12 months from the board's approval date [6][7] - As of September 30, 2025, the company has repurchased a total of 2.0055 million shares, with a cumulative repurchase amount of RMB 12.089 million (excluding transaction fees) [7] - The company is currently involved in legal proceedings due to a case involving the forgery of company seals, with 14 lawsuits from primary distributors totaling RMB 69.5026 million and 10 lawsuits from secondary distributors totaling RMB 17.0766 million [7] Financial Data - The financial statements for the third quarter have not been audited [3] - The company has confirmed that the financial information in the quarterly report is true, accurate, and complete, with no false records or significant omissions [2] - The company has not reported any non-recurring gains or losses for the current period [4][5]

Core Viewpoint - The company, Jimin Health, has announced its third-quarter financial report for 2025, highlighting its share repurchase plan and ongoing legal issues related to a fraud case involving a former employee [5][6]. Financial Data - The financial report for the first nine months of 2025 is unaudited, with no profits reported from merged entities [7][8]. - As of September 30, 2025, the company has repurchased 2,005,500 shares, totaling 12.089 million yuan (excluding transaction fees) [6]. Share Repurchase Plan - The company plans to repurchase shares using its own funds, with a maximum price of 10.00 yuan per share and a total repurchase amount between 100 million yuan and 200 million yuan, to be completed within 12 months from the board's approval [5]. Legal Issues - The company is currently facing 14 lawsuits from primary distributors involving 69.5026 million yuan and 10 lawsuits from secondary distributors involving 17.0766 million yuan due to a fraud case involving a former employee [6].

Core Viewpoint - Jimin Health (603222.SH) reported a significant decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved total operating revenue of 545 million yuan, representing a year-on-year decrease of 20.21% [1] - The net profit attributable to shareholders was -77.15 million yuan, a sharp decline from a net profit of 28.42 million yuan in the same period last year [1] - The basic earnings per share were -0.1473 yuan [1]

Core Viewpoint - Jimin Health reported a significant decline in revenue and net profit for the first three quarters of 2025, indicating financial challenges for the company [1][2]. Financial Performance - The company's revenue for the first three quarters was 545 million yuan, a year-on-year decrease of 20.21% [1]. - The net profit attributable to shareholders was -77.15 million yuan, a year-on-year decline of 371.51% [1]. - The net profit excluding non-recurring items was -76.54 million yuan, down 385.10% year-on-year [1]. - Basic earnings per share were -0.15 yuan [1]. Profitability Metrics - The gross margin for the first three quarters was 36.11%, down 7.14 percentage points year-on-year [2]. - The net margin was -13.84%, a decrease of 18.73 percentage points compared to the same period last year [2]. - In Q3 2025, the gross margin was 34.54%, down 6.31 percentage points year-on-year and down 1.58 percentage points quarter-on-quarter [2]. - The net margin for Q3 was -14.39%, a decline of 15.47 percentage points year-on-year, but an increase of 6.12 percentage points from the previous quarter [2]. Expense Analysis - Total operating expenses for the period were 235 million yuan, a decrease of 19.34 million yuan year-on-year [2]. - The expense ratio was 43.20%, an increase of 5.90 percentage points compared to the same period last year [2]. - Sales expenses decreased by 16.70%, while management expenses decreased by 1.51% [2]. - Research and development expenses increased by 0.79%, and financial expenses rose by 19.00% [2]. Company Overview - Jimin Health, established on December 24, 1996, is located in Taizhou, Zhejiang Province, and was listed on February 17, 2015 [3]. - The company's main business includes the research, production, and sales of medical devices, medical services, and large-volume infusion products [3]. - The revenue composition is as follows: pharmaceutical manufacturing 52.07%, medical services 46.01%, pharmaceutical trade 1.54%, and others 0.38% [3]. - Jimin Health is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables [3].

Financial Performance - The company's operating revenue for the third quarter was ¥178,268,850.64, a decrease of 17.86% compared to the same period last year[4]. - The total profit for the third quarter was -¥33,081,417.78, representing a decline of 1,749.03% year-on-year[4]. - The net profit attributable to shareholders was -¥24,454,507.27, down 923.38% from the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥23,334,321.39, a decrease of 1,054.49% year-on-year[4]. - The basic earnings per share for the third quarter was -¥0.0468, a decline of 920.18% compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2025 was ¥544.72 million, a decrease of 20.2% compared to ¥682.67 million in the same period of 2024[19]. - Net profit for the first three quarters of 2025 was a loss of ¥75.37 million, compared to a profit of ¥33.40 million in 2024, representing a significant decline[20]. - The total comprehensive income for the first three quarters of 2025 was a loss of ¥68.04 million, compared to a gain of ¥33.03 million in 2024[21]. - The company’s basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.1473, compared to ¥0.0538 in 2024[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,495,960,023.97, an increase of 3.38% from the end of the previous year[5]. - The equity attributable to shareholders decreased by 5.53% to ¥1,398,916,578.17 compared to the end of the previous year[5]. - The total liabilities increased to RMB 1,007,920,871.09 from RMB 846,220,952.60, representing a growth of approximately 19.1%[16]. - The company's total current liabilities reached RMB 665,932,667.63, an increase from RMB 486,577,856.37, reflecting a growth of approximately 37%[16]. - The company's equity attributable to shareholders decreased to RMB 1,398,916,578.17 from RMB 1,480,824,869.60, a decline of about 5.5%[16]. Cash Flow - The cash flow from operating activities for the year-to-date was -¥32,252,594.88, a decline of 172.82% compared to the previous year[4]. - The company reported a net cash outflow from operating activities of ¥32.25 million in 2025, compared to an inflow of ¥44.29 million in 2024[24]. - Cash and cash equivalents at the end of the third quarter of 2025 were ¥253.50 million, down from ¥172.60 million at the end of the same period in 2024[24]. - The company raised ¥397.88 million through financing activities in 2025, significantly higher than the ¥176.00 million raised in 2024[24]. - The company’s investment activities generated a net cash outflow of ¥191.31 million in 2025, compared to a smaller outflow of ¥88.21 million in 2024[24]. Inventory and Receivables - The company plans to further assess inventory impairment provisions due to reduced sales and market conditions affecting product lines[6]. - The company reported a decrease in inventory from RMB 174,108,449.24 to RMB 134,461,736.70, a reduction of about 22.8%[15]. - Accounts receivable rose to RMB 150,060,274.17, up from RMB 126,974,794.39, indicating an increase of about 18.2%[14]. Share Repurchase and Legal Matters - The company repurchased a total of 2,005,500 shares for a total amount of RMB 12,089,000 as of September 2025[13]. - The company plans to repurchase shares at a price not exceeding RMB 10.00 per share, with a total repurchase fund between RMB 100 million and RMB 200 million[12]. - The company is involved in ongoing legal cases with a total claim amount of RMB 6,950.26 million from primary distributors and RMB 1,707.66 million from secondary distributors[13]. Accounting Changes - The new accounting standards or interpretations will be implemented starting from 2025, affecting the financial statements at the beginning of the year of first-time application[25]. - The announcement was made by the board of directors of Jimin Health Management Co., Ltd. on October 31, 2025[26].